KR20200010217A - Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체 - Google Patents

Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체 Download PDF

Info

Publication number
KR20200010217A
KR20200010217A KR1020197033034A KR20197033034A KR20200010217A KR 20200010217 A KR20200010217 A KR 20200010217A KR 1020197033034 A KR1020197033034 A KR 1020197033034A KR 20197033034 A KR20197033034 A KR 20197033034A KR 20200010217 A KR20200010217 A KR 20200010217A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
sequence
cdr2
deletions
Prior art date
Application number
KR1020197033034A
Other languages
English (en)
Korean (ko)
Inventor
웬신 루오
시밍 강
이웬 왕
쿠안 유안
티안잉 장
닝샤오 시아
Original Assignee
시아먼 유니버시티
양셍탕 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시아먼 유니버시티, 양셍탕 컴퍼니 리미티드 filed Critical 시아먼 유니버시티
Priority to KR1020227030102A priority Critical patent/KR102561555B1/ko
Publication of KR20200010217A publication Critical patent/KR20200010217A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197033034A 2017-04-07 2018-04-08 Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체 KR20200010217A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227030102A KR102561555B1 (ko) 2017-04-07 2018-04-08 Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710223992.8 2017-04-07
CN201710223992 2017-04-07
PCT/CN2018/082157 WO2018184593A1 (zh) 2017-04-07 2018-04-08 用于治疗乙肝感染及相关疾病的抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030102A Division KR102561555B1 (ko) 2017-04-07 2018-04-08 Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체

Publications (1)

Publication Number Publication Date
KR20200010217A true KR20200010217A (ko) 2020-01-30

Family

ID=63712017

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197033034A KR20200010217A (ko) 2017-04-07 2018-04-08 Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체
KR1020227030102A KR102561555B1 (ko) 2017-04-07 2018-04-08 Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227030102A KR102561555B1 (ko) 2017-04-07 2018-04-08 Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체

Country Status (4)

Country Link
KR (2) KR20200010217A (ru)
CN (2) CN113480641B (ru)
RU (1) RU2765878C2 (ru)
WO (1) WO2018184593A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020233715A1 (zh) * 2019-05-23 2020-11-26 厦门大学 抗乙肝病毒抗体及其用途
CN115236331A (zh) * 2020-11-11 2022-10-25 南京诺唯赞生物科技股份有限公司 一种检测SARS-CoV-2中和抗体的试剂盒及方法
CN113683684B (zh) * 2021-06-21 2023-07-18 深圳市新产业生物医学工程股份有限公司 抗乙肝病毒表面抗原抗体、抗体对、含有其的检测试剂及试剂盒
CN115677852B (zh) * 2021-07-29 2023-11-10 东莞市朋志生物科技有限公司 一种抗HBeAg抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
JP4948783B2 (ja) * 2005-05-18 2012-06-06 シスメックス株式会社 抗ＨＢｓモノクローナル抗体
AP2010005354A0 (en) * 2008-01-23 2010-08-31 Acharya Subrat K A humanized high affinity recombinant antibody against hepatitis B surface antigen
DE102009028940A1 (de) * 2009-08-27 2011-03-03 Robert Bosch Gmbh Antriebsvorrichtung für eine Scheibenwischereinrichtung
KR101072895B1 (ko) * 2009-12-24 2011-10-17 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체
JP2013541937A (ja) * 2010-08-05 2013-11-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質
CN101943700A (zh) * 2010-09-10 2011-01-12 珠海丽珠试剂股份有限公司 乙型肝炎病毒表面抗原呈阳性的确认方法和试剂盒
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
KR101281098B1 (ko) * 2011-06-30 2013-07-02 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
CN103483421B (zh) * 2012-06-11 2019-10-22 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体
CN103588874B (zh) * 2013-11-11 2015-06-17 中国疾病预防控制中心病毒病预防控制所 一种人源抗乙肝病毒表面抗原基因工程抗体、其制备方法及应用
CN105001325A (zh) * 2015-07-31 2015-10-28 北京泰诺迪生物科技有限公司 一种全人源抗乙肝病毒中和抗体及其制备方法与应用
CN105061590B (zh) * 2015-08-03 2019-06-04 中国人民解放军第二军医大学 针对乙肝表面蛋白的双特异性抗体及其用途

Also Published As

Publication number Publication date
RU2019135404A3 (ru) 2021-05-07
CN113480641B (zh) 2023-04-11
RU2019135404A (ru) 2021-05-07
CN113480641A (zh) 2021-10-08
KR20220126788A (ko) 2022-09-16
CN108690134B (zh) 2021-07-30
RU2765878C2 (ru) 2022-02-04
CN108690134A (zh) 2018-10-23
WO2018184593A1 (zh) 2018-10-11
KR102561555B1 (ko) 2023-07-31

Similar Documents

Publication Publication Date Title
ES2789348T3 (es) Anticuerpos neutralizantes para GP120 y sus usos
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
KR102561555B1 (ko) Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체
KR102132604B1 (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
CN114174331B (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
KR102602564B1 (ko) 인터루킨-6의 인간 수용체에 결합가능한 항체 또는 항원 결합성 단편
JP2012513457A (ja) Ｈｃｖ感染の治療的処置および予防のための医薬としての抗ｈｃｖモノクローナル抗体
JP2014526886A (ja) マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
JP2021525071A (ja) Ｂ型肝炎抗体
JP7372638B2 (ja) 抗ｂ型肝炎ウイルス抗体及びその使用
RU2803082C2 (ru) Антитела против вируса гепатита в и их применение
US20230348568A1 (en) Epstein-barr virus monoclonal antibodies and uses thereof
TW202411246A (zh) 經工程化之b型肝炎病毒中和抗體及其用途
WO2021055798A1 (en) Influenza neutralizing antibodies and their uses
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
CN117480183A (zh) 抗il-36r抗体及其用途
CN114751987A (zh) 一种中和冠状病毒的多特异性抗体
CN117683123A (zh) 抗狂犬病毒人源化抗体和抗体组合及其用途
CN113549146A (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X601 Decision of rejection after re-examination
A107 Divisional application of patent